MedTrace Logo

Investigation of Naltrexone for Pathological Gambling

NCT01057862 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2017-10-13

Study results available
· View outcomes & findings →

Summary

The investigators plan to investigate the safety, tolerability, and efficacy of the opioid antagonist naltrexone in Pathological Gambling. We hypothesize that naltrexone will be superior to placebo in reducing gambling urges and behavior, when combined with adjuvant non-pharmacological treatment as usual.

Conditions

  • Pathological Gambling

Interventions

DRUG

Naltrexone

Targeted dosage of 50mg PO daily

OTHER

Placebo

Sugar pills daily PO

Sponsors & Collaborators

  • National Center for Responsible Gaming

    collaborator OTHER

  • Yale University

    lead OTHER

Principal Investigators

  • Marc N Potenza, M.D., Ph.D. · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2016-02-29
Completion
2017-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01057862 on ClinicalTrials.gov